Skip to content

Study · Measured the body's own peptide · 1997

6 results

Elevated plasma thymosin-alpha1 levels in lung cancer patients.

Sasaki H, Fujii Y, Masaoka A, Yamakawa Y, Fukai I, Kiriyama M, Saito Y, Matsui H

European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery1 Dec 1997Cited by 11 (Europe PMC)

PMID9489875 (opens in a new tab)DOI10.1016/s1010-7940(97)00269-8 (opens in a new tab)PepBankPUB-09489875
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

No result from this study comes from a test of the peptide.

Natural levels measured6

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01HumanEndogenous levelObservational studyOther

    In lung cancer patients, mean plasma levels of the body's own thymosin-alpha1 were higher than in normal individuals.

    In plain wordsIn people with lung cancer, the body's own thymosin-alpha1 level in blood was higher than in healthy people.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreasePlasma thymosin-alpha1 versus normal individuals
    Study

    n = 131

    Plasma, lung cancer patients
    Comparator
    Normal individuals
    Outcome group
    Endogenous peptide levels · Cancer

    Source sentences

    Summary
    We found that the mean plasma thymosin-alpha1 levels in lung cancer patients were higher than in normal individuals (P < 0.001).
    1 context sentence
    Summary · context
    In this investigation, we used this assay to measure plasma and tissue level of thymosin-alpha1 in 131 lung cancer patients.

    This result measures the body's own Thymosin alpha-1. Nobody was given the peptide. It is not evidence about taking it.

  2. 02HumanEndogenous levelObservational studyOther

    Half of the lung cancer patients had normal plasma levels of the body's own thymosin-alpha1.

    In plain wordsIn half of the people with lung cancer, the body's own thymosin-alpha1 level in blood was normal.

    Peptide
    Thymosin alpha-1
    Outcome
    MixedProportion of patients with normal plasma levels
    Study

    n = 131

    Plasma, lung cancer patients
    Outcome group
    Endogenous peptide levels · Cancer

    Source sentences

    Summary
    However, half of the patients showed normal levels.
    1 context sentence
    Summary · context
    In this investigation, we used this assay to measure plasma and tissue level of thymosin-alpha1 in 131 lung cancer patients.

    This result measures the body's own Thymosin alpha-1. Nobody was given the peptide. It is not evidence about taking it.

  3. 03HumanEndogenous levelObservational studyOther

    Plasma thymosin-alpha1 levels correlated neither with the stage nor with the pathological subtype of lung cancer.

    In plain wordsThe body's own thymosin-alpha1 level was not linked to the stage or type of lung cancer.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeCorrelation with stage and pathological subtype
    Study

    n = 131

    Plasma, lung cancer patients
    Outcome group
    Endogenous peptide levels · Cancer

    Source sentences

    Summary
    Thymosin-alpha1 levels correlated neither with the stage nor pathological subtype of the lung cancer
    1 context sentence
    Summary · context
    In this investigation, we used this assay to measure plasma and tissue level of thymosin-alpha1 in 131 lung cancer patients.

    This result measures the body's own Thymosin alpha-1. Nobody was given the peptide. It is not evidence about taking it.

  4. 04HumanEndogenous levelObservational studyOther

    Lung cancer patients with another cancer had higher plasma thymosin-alpha1 levels than those without evidence of other cancers.

    In plain wordsIn people with lung cancer, the body's own thymosin-alpha1 level was higher in those who also had another cancer.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreasePlasma level with another cancer
    Study

    n = 131

    Plasma, lung cancer patients
    Comparator
    Lung cancer patients without another cancer
    Outcome group
    Endogenous peptide levels · Cancer

    Source sentences

    Summary
    Thymosin-alpha1 levels of lung cancer patients with another cancer were higher than those without evidence of other cancers (P = 0.03).
    1 context sentence
    Summary · context
    In this investigation, we used this assay to measure plasma and tissue level of thymosin-alpha1 in 131 lung cancer patients.

    This result measures the body's own Thymosin alpha-1. Nobody was given the peptide. It is not evidence about taking it.

  5. 05HumanEndogenous levelObservational studyOther

    Survival of lung cancer patients with normal plasma thymosin-alpha1 levels was significantly better than that of patients with higher levels.

    In plain wordsPeople with lung cancer and normal levels of the body's own thymosin-alpha1 lived longer than those with higher levels.

    Peptide
    Thymosin alpha-1
    Outcome
    Not applicableSurvival by plasma level
    Study

    n = 131

    Plasma, lung cancer patients
    Comparator
    Patients with higher levels
    Outcome group
    Mortality · Cancer

    Source sentences

    Summary
    Survival of patients with normal levels of plasma thymosin-alpha1 was significantly better than that with higher levels (P = 0.04).
    1 context sentence
    Summary · context
    In this investigation, we used this assay to measure plasma and tissue level of thymosin-alpha1 in 131 lung cancer patients.

    This result measures the body's own Thymosin alpha-1. Nobody was given the peptide. It is not evidence about taking it.

  6. 06HumanEndogenous levelObservational studyOther

    Plasma thymosin-alpha1 levels did not decrease significantly in the 4 weeks after tumor resection.

    In plain wordsThe body's own thymosin-alpha1 level in blood did not fall significantly in the 4 weeks after the tumour was removed.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changePlasma level after tumor resection
    Study

    n: not reported in source

    Plasma, lung cancer patients
    Outcome group
    Endogenous peptide levels · Cancer

    Source sentences

    Summary
    and did not decrease significantly in the 4 weeks after the resection of the tumor.
    1 context sentence
    Summary · context
    In this investigation, we used this assay to measure plasma and tissue level of thymosin-alpha1 in 131 lung cancer patients.

    This result measures the body's own Thymosin alpha-1. Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:55 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.